Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

TG Therapeutics Inc

Healthcare US TGTX

41.61USD
1.50(3.74%)

Last update at 2026-06-04T18:11:00Z

Day Range

40.1042.48
LowHigh

52 Week Range

6.4629.32
LowHigh

Fundamentals

  • Previous Close 40.11
  • Market Cap2604.05M
  • Volume1332065
  • P/E Ratio56.17
  • Dividend Yield-%
  • EBITDA48.53M
  • Revenue TTM289.33M
  • Revenue Per Share TTM2.02
  • Gross Profit TTM 2.52M
  • Diluted EPS TTM0.30

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -198.33500M -348.10100M -279.38100M -172.87100M -173.48200M
Minority interest - - - - -
Net income -203.83100M -355.55200M -285.87800M -179.34700M -173.48200M
Selling general administrative 83.23M 152.14M 121.81M 20.84M 20.76M
Selling and marketing expenses 64.05M - 13.96M - 5.60M
Gross profit 2.52M 5.90M 0.15M 0.15M 0.15M
Reconciled depreciation 0.52M 0.28M 0.37M 0.28M 0.09M
Ebit -192.83900M -344.77000M -273.59400M -169.05500M -174.40000M
Ebitda -188.14400M -342.46300M -273.05200M -167.58400M -174.31200M
Depreciation and amortization 4.70M 2.31M 0.54M 1.47M 0.09M
Non operating income net other - 2.31M 0.54M 1.47M 0.92M
Operating income -192.83900M -344.77000M -273.59400M -169.05500M -174.40000M
Other operating expenses 195.62M 351.46M 273.75M 169.21M 174.55M
Interest expense 10.19M 5.64M 6.33M 5.29M 0.00000M
Tax provision - - - - -
Interest income - - - 5.29M 0.86M
Net interest income -10.19100M -5.63800M -6.32900M -5.28700M 0.86M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.50M 7.45M 6.50M 6.48M -0.91800M
Total revenue 2.79M 6.69M 0.15M 0.15M 0.15M
Total operating expenses 195.36M 350.67M 273.75M 169.21M 174.55M
Cost of revenue 0.27M 0.79M - - 0.00000M
Total other income expense net -5.49600M -3.33100M -5.78700M -3.81600M 0.06M
Discontinued operations - - - - -
Net income from continuing ops -182.64800M -348.10100M -279.38100M -172.87100M -173.48200M
Net income applicable to common shares -182.64800M -348.10100M -279.38100M -172.87100M -173.48200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 329.59M 193.57M 379.63M 625.64M 163.01M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 9.52M 6.60M 2.88M 1.08M 0.61M
Total liab 169.09M 134.99M 142.48M 106.29M 124.40M
Total stockholder equity 160.50M -1527.03300M -1328.69800M 519.35M -701.21600M
Deferred long term liab - 0.30M 0.46M 0.61M 0.76M
Other current liab 13.50M 9.30M 62.97M 63.71M 82.83M
Common stock 0.15M 0.15M 0.14M 0.14M 0.11M
Capital stock 0.15M 0.15M 0.14M 0.14M 0.11M
Retained earnings -1514.36100M -1527.03300M -1328.69800M -980.59700M -701.21600M
Other liab - 0.30M 0.46M 0.61M 0.76M
Good will 0.80M 0.80M 0.80M 0.80M 0.80M
Other assets 329.59M 2.90M 3.10M 13.10M 3.38M
Cash 92.93M 102.30M 298.89M 553.44M 112.64M
Cash and equivalents - - - - -
Total current liabilities 53.72M 53.20M 65.38M 87.55M 84.45M
Current deferred revenue 0.30M 0.30M 0.46M 0.61M -
Net debt 17.86M -19.24400M -219.84000M -511.46300M -71.83300M
Short term debt 1.45M 1.58M 2.41M 23.85M 1.62M
Short long term debt - - 0.97M 22.18M 0.19M
Short long term debt total 110.80M 83.06M 79.05M 41.98M 40.80M
Other stockholder equity 1674.71M -0.14600M -0.14300M 1499.81M -0.10900M
Property plant equipment - 0.31M 0.60M 0.48M 0.28M
Total current assets 317.94M 168.27M 330.96M 611.74M 149.15M
Long term investments 0.00000M 12.40M 35.53M - -
Net tangible assets - 57.79M 310.72M 518.55M 37.82M
Short term investments 124.58M 59.37M 15.88M 51.99M 27.80M
Net receivables 51.09M 0.00000M 1.39M - -
Long term debt 100.12M 71.14M 66.79M 7.72M 28.97M
Inventory 39.82M - -23.60400M - -
Accounts payable 38.47M 42.02M -0.45700M 37.01M 33.84M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -
Additional paid in capital - - - - -
Common stock total equity - 0.15M 0.14M 0.14M 0.11M
Preferred stock total equity - - - - -
Retained earnings total equity - -1527.03300M -1328.69800M -980.59700M -701.21600M
Treasury stock - - -0.23400M -0.23400M -0.23400M
Accumulated amortization - - - - -
Non currrent assets other 1.42M 1.27M 1.26M 1.26M 1.25M
Deferred long term asset charges - - - - -
Non current assets total 11.64M 25.30M 48.66M 13.90M 13.86M
Capital lease obligations 10.68M 11.93M 11.28M 12.08M 11.83M
Long term debt total - 71.14M 66.79M 7.72M 28.97M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -20.01300M 0.07M -24.51000M -0.71800M 1.18M
Change to liabilities -11.21700M -2.31900M -22.01400M 23.81M 29.16M
Total cashflows from investing activities -20.01300M -0.33200M -24.51000M -0.71800M 1.18M
Net borrowings -0.97500M 38.98M 40.00M 29.19M 29.99M
Total cash from financing activities -0.39100M 41.42M 679.83M 204.21M 113.64M
Change to operating activities 8.13M -26.66600M -31.23600M 30.14M 16.82M
Net income -198.33500M -348.10100M -279.38100M -172.87100M -173.48200M
Change in cash -196.57400M -254.54700M 440.81M 70.69M -14.10600M
Begin period cash flow 300.15M 554.70M 113.89M 43.20M 57.30M
End period cash flow 103.58M 300.15M 554.70M 113.89M 43.20M
Total cash from operating activities -176.17000M -295.63400M -214.50700M -132.80600M -128.92500M
Issuance of capital stock 0.00000M 2.22M 679.68M 175.02M 113.64M
Depreciation 0.52M 0.49M 0.37M 0.28M 0.09M
Other cashflows from investing activities -19.99900M 0.07M -24.15300M -0.58700M 1.27M
Dividends paid - 0.00000M - 0.00000M -
Change to inventory - - - - -
Change to account receivables 1.39M -1.38900M -0.00600M -1.38900M -1.38900M
Sale purchase of stock 0.58M 2.44M 679.83M 175.02M 113.64M
Other cashflows from financing activities 0.58M 69.20M 0.15M 29.19M 1.18M
Change to netincome 19.07M 60.70M 81.04M 11.46M 12.82M
Capital expenditures 0.01M 0.40M 0.36M 0.13M 0.09M
Change receivables 1.39M -1.38900M -0.00600M -0.01100M 0.01M
Cash flows other operating 10.90M -6.61200M 4.59M 4.01M 2.59M
Exchange rate changes - - - - -
Cash and cash equivalents changes -196.57400M -254.54700M 440.81M 70.69M -14.10600M
Change in working capital -1.64700M -12.21600M -19.75700M 25.19M 27.76M
Stock based compensation 19.18M 61.27M 80.29M 11.34M 12.89M
Other non cash items 4.11M 2.40M 4.00M 3.52M 3.94M
Free cash flow -176.18400M -296.03500M -214.86400M -132.93700M -129.01500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TGTX
TG Therapeutics Inc		 1.50 3.74% 41.61 56.17 140.85 9.36 13.62 8.90 79.69
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

TG Therapeutics Inc

3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560

Key Executives

Name Title Year Born
Mr. Michael S. Weiss Esq. Chairman, CEO & Pres 1966
Mr. Sean A. Power CPA, CPA CFO, Corp. Sec. & Treasurer 1982
Jenna Bosco Sr. VP of Corp. Communications NA
Mr. Adam Waldman Chief Commercialization Officer NA
Mr. Michael S. Weiss Esq. Chairman, CEO & President 1966
Mr. Sean A. Power CPA CFO, Corporate Secretary & Treasurer 1982
Jenna Bosco Senior Vice President of Corporate Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.